Floatz logo

Verdiperstat

Parkinson's Disease

AstraZenecaSmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

256 Active assets in the Parkinson's Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Pardoprunox
Abbott Products
Phase 3BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Istradefylline
Georgetown University
Phase 4BBB

View all 50 →

Same molecule, other indications

Verdiperstat is also rated in:

amyotrophic lateral sclerosisDormant
CCC
Indicative ·
55 / 100
View asset →
semantic dementiaDormant
CC
Indicative ·
43 / 100
View asset →
multiple system atrophyDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →